Page last updated: 2024-11-05

2,6-diaminoanthraquinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,6-Diaminoanthraquinone is a key intermediate in the synthesis of various dyes, pigments, and pharmaceuticals. It's a versatile molecule that finds application in a wide range of industries. It's primarily synthesized through the nitration of anthraquinone, followed by reduction to the diamine. The resulting compound exhibits strong color properties, making it valuable in textile dyeing and printing. Furthermore, its reactivity and functional groups allow for modifications and derivatization, leading to the creation of new compounds with specific properties. Research into 2,6-diaminoanthraquinone often focuses on developing novel synthetic routes to enhance its efficiency and sustainability. Its potential applications in organic electronics, as well as its biological activity as a potential antimicrobial agent, are also areas of active research.'

2,6-diaminoanthraquinone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID8557
CHEMBL ID90729
SCHEMBL ID516210
MeSH IDM0298634

Synonyms (45)

Synonym
BIDD:GT0328
CHEMBL90729
2,6-diamino-anthraquinone
2,6-diamino-9,10-anthraquinone
2,6-diaminoanthrachinon [czech]
9,10-anthracenedione, 2,6-diamino-
einecs 205-013-7
ai3-52500
ccris 5604
anthraquinone, 2,6-diamino-
brn 2809383
nsc 39935
anthraquinone,6-diamino-
nsc-39935
131-14-6
2,6-anthraquinonyldiamine
wln: l c666 bv ivj ez lz
2,6-diaminoanthrachinon
2,6-diaminoanthraquinone
9, 2,6-diamino-
nsc39935
2,6-diaminoanthraquinone, 97%
AC-10705
D3180
2,6-diaminoanthracene-9,10-dione
FT-0659881
A806207
2,6-bis(azanyl)anthracene-9,10-dione
4-14-00-00486 (beilstein handbook reference)
3dy0euz2zm ,
unii-3dy0euz2zm
AKOS015855591
2,6-diaminoanthra-9,10-quinone
SCHEMBL516210
DTXSID5059614
mfcd00001234
2,6-diaminoanthra-9,10-quinone #
sr-01000359144
SR-01000359144-1
J-005941
CS-W014150
AS-10992
Q27257090
SY051468
YSWG023
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (7)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.00071.600310.0000AID144609; AID144610
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.00071.630610.0000AID144609; AID144610
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.00061.525710.0000AID144609; AID144610
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.00071.747210.0000AID144609; AID144610
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.00071.741110.0000AID144609; AID144610
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.00071.741110.0000AID144609; AID144610
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.00071.741110.0000AID144609; AID144610
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1888752Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using kynuramine as substrate at 100 uM after 20 mins by fluorescence spectrophotometric assay2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Phenothiazine, anthraquinone and related tricyclic derivatives as inhibitors of monoamine oxidase.
AID144609Displacement of [3H]MK-801 from N-methyl-D-aspartate glutamate receptor2000Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23
Aminoanthraquinones as novel ligands at the polyamine binding site on the N-methyl-D-aspartate receptor complex.
AID1888751Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate at 100 uM after 20 mins by fluorescence spectrophotometric assay2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Phenothiazine, anthraquinone and related tricyclic derivatives as inhibitors of monoamine oxidase.
AID144610Displacement of [3H]-SPD from N-methyl-D-aspartate glutamate receptor2000Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23
Aminoanthraquinones as novel ligands at the polyamine binding site on the N-methyl-D-aspartate receptor complex.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (12.50)18.2507
2000's4 (50.00)29.6817
2010's2 (25.00)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.93 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index32.00 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]